RT Journal Article
SR Electronic
T1 Quantification of different iron forms in the aceruloplasminemia brain to explore iron-related neurodegeneration
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.15.20206102
DO 10.1101/2020.10.15.20206102
A1 Lena H.P. Vroegindeweij
A1 Lucia Bossoni
A1 Agnita J.W. Boon
A1 J.H. Paul Wilson
A1 Marjolein Bulk
A1 Martina Huber
A1 Jacqueline Labra-Muñoz
A1 Andrew Webb
A1 Louise van der Weerd
A1 Janneke G. Langendonk
YR 2020
UL http://medrxiv.org/content/early/2020/10/26/2020.10.15.20206102.abstract
AB Introduction Aceruloplasminemia is an ultra-rare neurodegenerative disorder associated with massive brain iron accumulation. It is unknown which molecular forms of iron accumulate in the brain of patients with aceruloplasminemia. As the disease is associated with at least a fivefold increase in brain iron concentration compared to the healthy brain, it offers a unique model to study the role of iron in neurodegeneration and the molecular basis of iron-sensitive MRI contrast.Methods The iron-sensitive MRI metrics inhomogeneous transverse relaxation rate (R2*) and magnetic susceptibility obtained at 7T were combined with Electron Paramagnetic Resonance (EPR) and Superconducting Quantum Interference Device (SQUID) magnetometry to specify and quantify the different iron forms per gram wet-weight in a post-mortem aceruloplasminemia brain, with focus on the basal ganglia, thalamus, red nucleus, dentate nucleus, superior-and middle temporal gyrus and white matter. MRI, EPR and SQUID results that had been previously obtained from the temporal cortex of healthy controls were included for comparison.Results The brain iron pool in aceruloplasminemia consisted of EPR-detectable Fe3+ ions, magnetic Fe3+ embedded in the core of ferritin and hemosiderin (ferrihydrite-iron), and magnetic Fe3+ embedded in oxidized magnetite/maghemite minerals (maghemite-iron). Of all the studied iron pools, above 90% was made of ferrihydrite-iron, of which concentrations up to 1065 µg/g were detected in the red nucleus. Although deep gray matter structures in the aceruloplasminemia brain were three times richer in ferrihydrite-iron than the temporal cortex, ferrihydrite-iron in the temporal cortex of the patient with aceruloplasminemia was already six times more abundant compared to the healthy situation (162 µg/g vs. 27 µg/g). The concentration of Fe3+ ions and maghemite-iron were 1.7 times higher in the temporal cortex in aceruloplasminemia than in the control subjects. Of the two quantitative MRI metrics, R2* was the most illustrative of the pattern of iron accumulation and returned relaxation rates up to 0.49 ms-1, which were primarily driven by the abundance of ferrihydrite-iron. Maghemite-iron did not follow the spatial distribution of ferrihydrite-iron and did not significantly contribute to MRI contrast in most of the studied regions.Conclusions Even in extremely iron-loaded cases, iron-related neurodegeneration remains primarily associated with an increase in ferrihydrite-iron, with ferrihydrite-iron being the major determinant of iron-sensitive MRI contrast.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Dutch Foundation for Fundamental Research on Matter (FOM), by the Netherlands Organization for Scientific Research (NWO) through a VENI fellowship to L.B. (0.16.Veni.188.040), and a grant from the ZonMw program Innovative Medical Devices Initiative, project Imaging Dementia: Brain Matters (104003005) to M.B. M.H. and J. L.-M. are founded by the NWO Zwartekrachtprogram, Nanofront project NF17SYN05.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has received IRB approval by the Erasmus MC Medical Ethical Committee (MEC-2011-525).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request of the corresponding author